This article is more than 5 years old. Information may no longer be current.
Quantel Medical to market Iridex MicroPulse laser
Iridex has signed a global patent licensing agreement that will allow Quantel Medical to market Iridex’s MicroPulse technology, according to a news release.
The agreement will help to broaden the market availability for MicroPulse photocoagulation lasers, the release said.
“The global clinical evidence supporting Iridex’s MicroPulse laser technology was an important factor in this decision," Jean-Marc Gendre, CEO of Quantel, said in the release. “By aligning our market strategies with another industry leader, we believe the ophthalmic community will have greater access to MicroPulse technology, helping to improve the standard of care for retinal diseases. We also believe that this collaboration will be the most efficient method to standardize MicroPulse clinical protocols for our customers.”
MicroPulse is a tissue-sparing therapy that electronically divides laser emissions into trains of microsecond pulses, enabling physicians to better control the impact on target tissue and reduce collateral effects compared to conventional laser treatment, according to the release.